Company
Arthex Biotech
- Biotech
Description
Arthex Biotech develops RNA-based therapeutics, including an anti‑miR program delivered via fatty‑acid conjugated oligonucleotides to improve muscle tissue delivery and treat myotonic dystrophy.
Related
Gate2BrainGate2Brain produces a peptide-based, patented technology platform of three peptide-shuttle families that improve delivery and…
NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
Phlox TherapeuticsPhlox Therapeutics develops precision RNA-based therapies to treat rare genetic cardiomyopathies, creating therapeutic candidates and…
KerecisKerecis develops, manufactures, and distributes fish-skin medical devices that use intact fish skin and fatty acids as a scaffold for cell…
EurogentecEurogentec provides life-science products and CDMO manufacturing for research, diagnostics and therapeutics, producing oligonucleotides,…
OrexoOrexo develops powder-based drug delivery technologies and therapeutic formulations, including AmorphOX®, used to improve bioavailability…
INNITIUSINNITIUS develops medical hardware and software that measure cervical tissue mechanical properties using torsional-wave sensing and AI to…
CollimateHealthCollimateHealth develops microbeam radiation systems that deliver arrays of extremely narrow radiation beams to treat tumors while sparing…
- AplagonAplagon develops a therapeutic called APAC, a vascular-injury targeting molecule that combines antiplatelet, anticoagulant, and…